AbbVie的动态

The recent FDA approval of G12C KRAS inhibitors marks a crucial milestone in cancer treatment. Despite this, the initial response is limited and many patients relapse. A comprehensive KRAS-dependent transcriptional signature could be the key to broader and more durable responses. This research by Jeff Klomp and others, highlights a robust KRAS gene signature enriched in response to pharmacologic inhibition. This signature, driven by ERK MAPK activity, is essential for understanding how KRAS mutations drive cancer. Can these insights lead to better clinical outcomes for KRAS-mutant cancer patients? See link to original article in the comments below ?? #CancerResearch #KRASInhibitors #PrecisionMedicine #Oncology ?? Follow xCures Read our LinkedIn Newsletter:?https://lnkd.in/dnNJV2ti https://xcures.com/ ??

???? Norway's precision medicine revolution is taking the fight to cancer! Discover how biotech companies like Nykode Therapeutics are teaming up with global pharma to develop innovative cancer vaccines and therapies. The IMPRESS-Norway clinical trial is paving the way for improved public cancer care through precision medicine. Want to know more about Norway's thriving ecosystem and its impact on cancer treatment? Click to learn more?? #PrecisionMedicine #CancerResearch #BiotechInnovation #NorwegianHealthcare #InvestInNorway

What if we could accurately predict if a cancer drug will work - before a patient begins treatment??? ? WEHI researchers have used tumour #organoids – 3D cancer models grown from a patient’s own tissue – to do exactly that.? ? The research, led by Dr Tao Tan, Professor Peter Gibbs and Associate Professor Oliver Seiber, found organoid drug testing can predict how patients with advanced bowel cancer will respond to treatment with 83% accuracy.? ? It’s the first study in the world to prove patient-derived #tumour organoids can be used to pre-test the effectiveness of available treatment options and identify potential new therapies people living with bowel cancer – the second-deadliest cancer in Australia.? ? A clinical trial based on the findings is now in development.? ? Brilliant research, published in Cell Reports Medicine (Cell Press).?? ? #ClinicalTrial #BowelCancer #CancerTreatments #MedicalResearch

Next week we’ll be attending #ASCO24 in Chicago. We’re looking forward to learning the latest advancements in cancer care and connecting with 40,000 oncology professionals from around the world. The theme for this year’s meeting is “The Art and Science of Cancer Care: From Comfort to Cure.”?The sessions will also examine state-of-the-art approaches in disease sites and biologics in lung cancer and biomarkers. What are you most excited about at ASCO? Let us know in the comments! #lungcancer #innovation #cancerresearch #oncology #ASCOChicago #CIZ

The Cancer Research Institute and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003,?a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the IPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers. “There is a large body of clinical evidence for LOQTORZI, including positive phase 3 studies published in top-tier scientific journals, showing efficacy and safety in multiple tumor types,” says Jay Campbell, Managing Director, Clinical Accelerator and Venture Fund at CRI. “This level of scientific evidence is what we are looking for when selecting immunotherapies to bring into our network, with the goal of advancing clinically meaningful solutions to patients. We are grateful to have the opportunity to collaborate with Coherus BioSciences and ENB Therapeutics on this study and excited to be working with them on this novel combination that we hope will lead to improved outcomes in these patient populations.” More: https://bit.ly/3QzMzH8 #OvarianCancer #CancerResearch

?? This September, during Prostate Cancer Awareness Month, Heidelberg Pharma AG stands in solidarity with the millions of men and their families affected by #ProstateCancer. ? Prostate cancer is the most common cancer in men, with cases expected to nearly double by 2040. ? At #HeidelbergPharma, our mission is to create inspired medicines for those diagnosed with this serious disease to enhance treatment options and survival rate. Our preclinical candidate, HDP-103, a PSMA-ATAC, is specifically designed to target metastatic castration-resistant prostate cancer - a particularly challenging form of the disease. ? ?? Collectively, we can make a difference in the fight against prostate cancer! ? #ADCs #ATAC #ProstateCancerMonth?#CancerResearch

A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - Neeraj Agarwal, MD, FASCO Rana McKay Alicia Morgans OncoAlert UroToday + GU OncToday Prostate Cancer Foundation #Cancer #OncoDaily #Oncology #ProstateCancer

Smoking Cessation services are essential to cancer treatment success and long term survival; essential for cancer prevention and cancer control.

The ability to detect oncology biomarkers at ultra-low levels is a game-changer for cancer research. With Simoa? assays, there are new possibilities for diagnostics and treatment, offering the potential to: ?? Monitor cancer risk ?? Identify early-stage cancers ?? Discriminate between benign and malignant cells Simoa? biomarkers also hold promise for prognostic use, such as predicting disease outcomes, monitoring progression-free survival, tracking recurrence, and guiding treatment decisions. Explore our available assays and related publications to see how Simoa? can advance your oncology research: https://bit.ly/3XALFNq #Oncology #CancerResearch #Biomarkers #Diagnostics

?A comprehensive review of PARPi+ARPI combos in 1st line mCRPC